A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

• Status: Recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merus N.V.
• Collaborators: Chiltern International Inc.; Covance; LGC Limited
• Treatments: Antibodies; Antibodies, Bispecific; Immunoglobulins

Criteria

Inclusion Criteria:

• At least one measurable lesion according to RECIST v1.1 OR evaluable disease for a limited number of patients (up to 10) in Group H;

• Performance status of ECOG 0 or 1;

• Estimated life expectancy of at least 12 weeks;

• Toxicities incurred as a result of previous anti-cancer therapy resolved to ≤Grade 1;

• Treatment with anti-cancer medication or investigational drugs within the following intervals before the first dose of MCLA-128:

1. >14 days or >5 half-lives prior to study entry, whichever is shorter.

2. >14 days for radiotherapy.

• Recovery from major surgery or other complication to ≤ Grade 2 or baseline ;

• Absolute neutrophil count ≥1.5 x 109/L without colony stimulating factor support;

• Platelets ≥100 x 109/L;

• Hemoglobin ≥8 g/dL or ≥2.2 mmol/L;

• Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) and total bilirubin ≤1.5 x ULN; in cases of metastatic liver involvement, ALT/AST ≤5 x ULN and total bilirubin ≤2 x ULN will be allowed; in cases of antecedents of Gilbert's syndrome when total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x ULN will be allowed;

• Estimated glomerular filtration rate (GFR) of >30 mL/min

• Able to provide a tumor biopsy sample (fresh strongly preferred or else archival);

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for 6 month after completion of study therapy;

• Patients must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy;

• Locally-advanced unresectable or metastatic solid tumor malignancy with documented NRG1 gene fusion, identified through molecular assays such as PCR, next generation sequencing-based assays [DNA or RNA], or FISH as routinely performed at CLIA or other similarly-certified laboratories.

Exclusion Criteria:

• Pregnant or lactating;

• Presence of an active uncontrolled infection or an unexplained fever;

• Known hypersensitivity to any of the components of MCLA-128;

• Known HIV, active Hepatitis B or Hepatitis C; patients treated for Hepatitis C and have undetectable viral loads are eligible

• Known symptomatic or unstable brain metastases;

• Patients with leptomeningeal metastases

• Presence of congestive heart failure or Left Ventricular Ejection Fraction<50% or history of significant cardiac disease, unstable angina, myocardial infarction or ventricular arrhythmia requiring medication.

• Previous or concurrent malignancy (excluding non-basal cell carcinoma of skin or carcinoma in situ of the uterine cervix) unless the tumor was treated with curative intent more than 2 years prior to study entry;

• Presence of any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate or participate in the study, or interfere with the interpretation of the results.